New Bill Aims to Cap Insulin Prices at $35 for Patients

Thu Apr 02 2026 06:20:14 GMT+0000 (Coordinated Universal Time)

A new bipartisan bill introduced in Congress seeks to limit insulin costs for Americans with private insurance plans, as the rising price of this vital medication continues to burden families across the nation.

In an effort to alleviate the financial stress of insulin costs for diabetes patients, a bipartisan group of senators has introduced the INSULIN Act, which would cap monthly insulin prices at $35 for individuals with private insurance. The legislation aims to address the high out-of-pocket expenses faced by many diabetes patients, including young families like that of two-year-old Bain Brandon, who suffers from Type 1 diabetes. While similar past initiatives have encountered obstacles, advocates remain hopeful that this new effort will succeed in providing much-needed relief.

NEW YORK (RTWNews) — Two-year-old Bain Brandon depends on insulin to manage his Type 1 diabetes, but with health insurance, his family still faces significant costs. Recently, his monthly supply of insulin totaled $194, leaving his mother, Marlee Brandon, concerned about future affordability as her son grows up.

In response to these escalating costs, a bipartisan coalition of senators has introduced the INSULIN Act. This proposed legislation aims to cap insulin prices at $35 per month for Americans with private insurance and also initiates a pilot program to increase insulin accessibility for uninsured individuals in ten states.

The bill builds on previous bipartisan efforts and follows a 2022 law that established a similar cap for Medicare beneficiaries. Nevertheless, the INSULIN Act faces hurdles, including concerns over legislative costs and competing priorities in Congress—yet it presents a unique bipartisan opportunity amid widespread concern about rising healthcare expenses.

Approximately 8.1 million U.S. citizens rely on insulin, and the variability in pricing poses a significant issue, with some patients facing exorbitant monthly costs while others experience much lower expenses. Recent actions by major insulin manufacturers to reduce list prices aim to improve this situation, but many patients remain uninsured or are unable to access savings programs.

Despite the challenges, diabetes advocates maintain hope that the INSULIN Act might provide essential financial relief, particularly for young adults who struggle to secure affordable insurance coverage. As lawmakers prepare to discuss this initiative, families like the Brandons are eager for a breakthrough in achieving accessible healthcare.